Clinical Trials Browser

Colorectal Neoplasms

Gastric Cancer With Liver Metastases

Anatomic Stage II Breast Cancer AJCC v8

Leukemia, Myeloid, Acute

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Sleep Initiation and Maintenance Disorders

Triple Negative Breast Neoplasms

Lung Neoplasms

Stomach Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Gastroesophageal Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Muscle-invasive Bladder Cancer

Squamous Cell Carcinoma of Head and Neck

Anus Neoplasms

Pathologic Complete Response, Rectal Neoplasms

Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

Breast Neoplasms

Small Cell Lung Carcinoma

Pancreatic Cancer Metastatic

Pancreatic Neoplasms

Pancreatic Cancer Liver Metastases

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung

Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

Carcinoma, Non-Small-Cell Lung

Urinary Bladder Neoplasms

Pancreatic Neoplasms

Uterine Cervical Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Rectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Breast Neoplasms, Triple Negative Breast Neoplasms

Disease, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Mesothelioma, Malignant, Mesothelioma

Clinical Trials

PACHA-02

TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC

THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

VVSHIP

FREEDOM

Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

INSTAR

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

HER-OIC

GIVEN

SYS6090 Combination Therapy in Advanced Lung Cancer

Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

TD-NEOE3V3

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Adjuvant Chemotherapy for BTC Based on 3D-PTA

HYPERBOLIC

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

AssiutU

Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

REFIRT

[18F]-AraG PET Imaging in LA HNSCC

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

SMARTi-RC01

Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

PRIME-Lung

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma